Lack of Electrocardiographic Effects of Deucravacitinib in Healthy SubjectsAnjaneya Chimalakonda, Bindu Murthy, Ihab Girgis et al.|Clinical Pharmacology in Drug Development|2022Cited by 12
Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in HumansAnjaneya Chimalakonda, Bindu Murthy, Wenying Li et al.|Clinical Pharmacology in Drug Development|2023Cited by 2
Lack of ECG effects of BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: results from a thorough QT study in healthy subjectsIG Girgis, Subhashis Banerjee, John Throup et al.|SKIN The Journal of Cutaneous Medicine|2019Cited by 0